Recent Updates
Recently added Catalysts
SIBN Positive Sentiment Score: 75/100

SI-BONE to Present at Bank of America Merrill Lynch 2023 Global Healthcare Conference

Key Takeaway: SI-BONE, Inc. will participate in the 2023 Bank of America Merrill Lynch Global Healthcare Conference on May 9, 2023, in Las Vegas. The company will host a fireside chat, providing an opportunity to engage with investors. SI-BONE is recognized for its iFuse Implant System, which has been instrumental in treating musculoskeletal disorders and is supported by comprehensive clinical evidence.

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a prestigious global healthcare conference enhances visibility.
  • Management hosting a fireside chat indicates strong engagement with investors.
  • The company has a proven track record with the iFuse Implant System, with extensive published evidence.

Full Press Release Details

SANTA CLARA, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming 2023 Bank of America Merrill Lynch Global Healthcare Conference in Las Vegas. Management will be hosting a fireside chat on Tuesday, May 9th, 2023, at 1:55 p.m. Eastern Time / 10:55 a.m. Pacific Time.
A live webcast of each event, as well as an archived recording will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcasts will be archived and available for replay for at least 90 days after the event.
SI-BONE (NASDAQ: SIBN) is a global leader in technology for surgical treatment of musculoskeletal disorders of the sacropelvic anatomy. Since 2009, when SI-BONE introduced the iFuse Implant System for minimally invasive surgery of the SI joint, nearly 3,000 surgeons have performed a combined total of more than 80,000 SI joint fusion procedures. A unique body of evidence, supporting the iFuse Implant System, including two randomized controlled trials and over 120 peer reviewed publications, has enabled multiple government and private insurance payors to establish near-universal coverage of minimally invasive SI joint fusion, including many payors that cover the procedure exclusively when performed with the iFuse Implant System. Supported by this proprietary reimbursement advantage, SI-BONE has actively leveraged its market leadership position in recent years to further clinical research and evolve and commercialize novel surgical treatment solutions for SI-Joint pain, sacropelvic and pelvic fixation, and pelvic trauma.
For additional information on the company or the products including risks and benefits, please visit https://si-bone.com/.

Frequently Asked Questions

When is SI-BONE's fireside chat at the healthcare conference?

The fireside chat will be on May 9th, 2023, at 1:55 p.m. Eastern Time.

How can I access the webcast of the SI-BONE event?

The webcast will be available in the 'Investors' section of their website.

What is the iFuse Implant System used for?

The iFuse Implant System is designed for minimally invasive SI joint surgery.

How many SI joint fusion procedures have been performed using iFuse?

Over 80,000 SI joint fusion procedures have been conducted using the iFuse system.

What support does the iFuse Implant System have?

The system is backed by two randomized controlled trials and over 120 publications.

Last updated: Apr 24, 2023